▎药明康德内容团队编辑日前，阿斯利康（AstraZeneca）与安进（Amgen）合作开发的“first-in-class”单抗Tezspire（tezepelumab）针对伴有鼻息肉的慢性鼻窦炎（CRSwNP）患者进行的WAYPOINT临床3期试验 ...

在最新的试验结果中，Tezspire治疗组展现出了统计学和临床意义上显著的改善，这标志着在慢性鼻窦炎及鼻息肉治疗方法上的一大突破。这项研究结果为进一步的临床应用奠定了基础，同时也为医务人员提供了新的武器，以更有效地帮助患者。

公开资料显示，Tezepelumab是阿斯利康与安进共同开发的一款first-in-class单克隆抗体，可抑制胸腺基质淋巴细胞生成素 (TSLP)。TSLP是一种关键的上皮细胞因子，位于多种炎症级联反应的上游，与哮喘、CRSwNP、慢性阻塞性肺疾病 ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

Rheumatoid arthritis is an independent risk factor for CRSwNP recurrence after surgery, linked to higher tissue eosinophil counts, according to a recent study.

周二，Piper Sandler开始对Upstream Bio (NASDAQ:UPB)股票进行覆盖，给予增持评级，并设定75.00美元的目标价。 该公司强调了Upstream Bio的主要候选药物verekitug的潜力，因其独特的作用机制 ...

周二，TD Cowen对Upstream Bio (NASDAQ:UPB)给予积极展望，该公司以"买入"评级开始对这家生物科技公司的股票进行覆盖。这种乐观态度基于Upstream Bio的哮喘治疗药物verekitug (TSLPR mAb)的前景看好，该药物被视为市场上的强劲竞争者。 TD Cowen强调，verekitug在其第一阶段试验中已经显示出对哮喘生物标志物的快速、深入和持久的影响。与 ...

The following is a summary of “Real-world effectiveness of dupilumab in a European cohort of CRSwNP (CHRINOSOR),” published in the October 2024 issue of Allergy and Immunology by Seys et al. Pivotal ...

Tessa Romero, an analyst from J.P. Morgan, has initiated a new Buy rating on Upstream Bio, Inc. (UPB). Tessa Romero’s rating is based on ...

Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP –– Commenced startup for a Phase 2 clinical trial in ...